← Patent-cliff monitor Loss of exclusivity August 2029 latest FDA-listed patent expiry
Drug detail Brand name INVOKAMET XR Active ingredient CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE Strength 50MG;1GM Dosage form TABLET, EXTENDED RELEASE Route ORAL Modality Small molecule FDA approval September 2016 Marketing status RX
Listed patents Patent Expires Type 7943582*PED August 2029 — 7943582 February 2029 substance, product 8513202*PED June 2028 — 7943788*PED January 2028 — 8513202 December 2027 substance, product 7943788 July 2027 substance, product
Regulatory exclusivity Code Expires PED June 2028 NPP December 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.